Updates are available Correction dated 2021-07-06
Click to view Correction: https://doi.org/10.1007/s10549-021-06268-7
-
Authors
Leone, José P. https://orcid.org/0000-0002-8537-652X
Vallejo, Carlos T.
Hassett, Michael J.
Leone, Julieta
Graham, Noah
Tayob, Nabihah
Freedman, Rachel A.
Tolaney, Sara M.
Leone, Bernardo A.
Winer, Eric P.
Lin, Nancy U.
- License Information
-
More Information
Article History
Received: 11 March 2021
Accepted: 16 April 2021
First Online: 24 April 2021
Change Date: 6 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10549-021-06268-7
Declarations
:
: JPL has received research funding from Kazia Therapeutics and Merck. MJH received research support from the National Institute of Health, American Cancer Society, Brown Performance Group, and IBM. RAF has received institutional research funding from Puma Biotechnology. SMT has received institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odonate, Sanofi, and Nektar. SMT has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Paxman, Athenex, Oncopep, Daiichi-Sankyo, G1 Therapeutics, Silverback Therapeutics, Kyowa Kirin Pharmaceuticals, AbbVie, Sanofi, Seattle Genetics, Celldex, Bristol-Myers Squibb, and Nanostring. EPW has received consultant honoraria from Carrick Therapeutics, G1 Therapeutics, Genentech/Roche, Genomic Health, GSK, Jounce, Leap, Lilly, Novartis, Seattle Genetics, Syros; scientific advisory board for Leap; institutional research support from Genentech/Roche. NUL has received institutional research funding from Genentech, Merck, Seattle Genetics, and Pfizer, and has served as an advisor/consultant to Seattle Genetics, AstraZeneca, Daiichi-Sankyo, Denali Therapeutics, and the California Institute for Regenerative Medicine. All other authors have declared no conflicts of interest.
: Given that only deidentified data were used for this study, the study was considered exempt from Dana-Farber Cancer Institute’s Institutional Review Board review.
